Oral Oncology
Volume 40, Issue 5 , Pages 461-473 , May 2004

Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention

Received 17 September 2003 ,Accepted 24 September 2003.

References 

  1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA. Cancer J. Clin. 1999;49:33–36
  2. Parkin DM, Posani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer. 1993;54:594–606
  3. Hannahan D, Weinberger . The hallmark of cancer. Cell. 2000;100:57–70
  4. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 1999;11:68–75
  5. Ker JFK, Wyllie AH, Currie AR. Apoptosis, a basic biological phenomena with wider implications in tissue kinetics. Brit. J. Cancer. 1972;26:239–245
  6. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature. 2000;407(6805):810–816
  7. Otani Y, Tsutsumi K, Kuwahara D, Oyake D, Ohta T, Nishika H, et al.  Sensitization of head and neck squamous cell carcinoma cells to Fas-mediated apoptosis by inhibition of Bcl-X(L) expression. Auris Nasus Larynx. 2003;30(Suppl.):S79–S84
  8. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell. Biol. 1998;10(2):262–267
  9. Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S, et al.  Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J. Biol. Chem. 2001;276(3):2221–2227
  10. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell. Biol. 2001;2(8):589–598
  11. Schwab BL, Guerini D, Didszun C, Bano D, Fernando-May E, Fava E, et al.  Cleavage of plasma membrane calcium pump by caspases: a link between apoptosis and necrosis. Cell Death Differ. 2002;9:818–831
  12. Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 2001;11:526–534
  13. Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem. 2001;276(10):7320–7326
  14. Gross A, McDonnell JM, Korsmyer SJ. Bcl-2 family members and mitochondria in apoptosis. Genes Develop. 1999;13:1891–1911
  15. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, et al.  Bid, bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 2002;111:331–342
  16. Tafani M, Karpinich NO, Hurster KA, Pastorino JG, Schneider T, Russo MA, et al.  Cytochrome c release upon Fas receptor activation depends on translocation of full-length bid and the induction of the mitochondrial permeability transition. J. Biol. Chem. 2002;277(12):10073–10082
  17. Mathiasen IS, Jaattela M. Triggering caspase-independent cell death to combat cancer. Trends Mol. Med. 2002;5:212–228
  18. Evans GL, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–348
  19. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 2000;36(3):256–263
  20. Stoll C, Baretton G, Ahrens C, Lohrs U. Prognostic significance of apoptosis and associated factors in oral squamous cell carcinoma. Virchows Arch. 2000;436(2):102–108
  21. Regezi JA, Jordan RC. Oral cancer in the molecular age. J. Calif. Dent. Assoc. 2001;29(8):578–584
  22. In:  Regezi JA,  Sciubba JJ,  Jordan RCK editor. Oral pathology. 4th ed.. W.B. Saunders; 2003;p. 52–72 [Chapter 2, p. 23–74]
  23. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncol. 2000;36(4):311–327
  24. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, et al.  p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. 2000;6(3):916–923
  25. Kudo Y, Takata T, Ogawa I, Zhao M, Sato S, Takekoshi T, et al.  Reduced expression of p27 (Kip1) correlates with an early stage of cancer invasion in oral squamous cell carcinoma. Cancer Lett. 2000;151(2):217–222
  26. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J. Clin. 2002;52(4):195–215
  27. Scully C. Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral Oncol. 2002;38(3):227–234
  28. Jefferies S, Foulkes WD. Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncol. 2001;37:115–126
  29. Nunn J, Nagini S, Risk JM, Prime W, Maloney P, Liloglou T, et al.  Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3, in squamous cell carcinoma of the head and neck. Oral Oncol. 2003;39(2):115–129
  30. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767
  31. Califano J, Van Der Reit P, Westra W. Genetic progression model for head and neck cancer implications for field cancerization. Cancer Res. 1996;56:2488–2492
  32. Schwartz JL. Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis. Crit. Rev. Oral Biol. Med. 2000;11:92–122
  33. Piboonniyom SO, Timmermann S, Hinds P, Munger K. Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity. Oral Oncol. 2002;38(2):179–186
  34. Todd R, Hinds PW, Munger K, Rustgi AK, Opitz OG, Suliman , et al.  Cell cycle dysregulation in oral cancer. Crit. Rev. Oral Biol. Med. 2002;13(1):51–61
  35. Hsu S, Yu FS, Lewis J, Singh B, Borke J, Osaki T, et al.  Induction of p57 is required for cell survival when exposed to green tea polyphenols. Anticancer Res. 2002;22:4115–4120
  36. Fujieda S, Inuzuka M, Tanaka N, Sunaga H, Fan GK, Ito T, et al.  Expression of p27 is associated with BAX expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int. J. Cancer. 1999;84(3):315–320
  37. Tsuzuki H, Fujieda S, Sunaga H, Narita N, Tokuriki M, Saito H. Expression of p27 and apoptosis in oral leukoplakia. Anticancer Res. 2003;23:1265–1270
  38. Warnakulasuriya KA, Tavassoli M, Johnson NW. Relationship of p53 overexpression to other cell cycle regulatory proteins in oral squamous cell carcinoma. J. Oral Pathol. Med. 1998;27(8):376–381
  39. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al.  WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–825
  40. Feinberg AP. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res. 1999;9(Suppl. 7):1743s–1746s
  41. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O’Keefe CL, et al.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 1994;8:2939–2952
  42. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993;7:331–342
  43. Opalka B, Dickopp A, Kirch HC. Apoptotic genes in cancer therapy. Cells Tissues Organs. 2002;172(2):126–132
  44. Koontongkaew S, Chareonkitkajorn L, Chanvitan A, Leelakriangsak M, Amornphimoltham P. Alterations of p53, pRb, cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol. 2000;36(4):334–339
  45. Schmitt CA, Low SW. Apoptosis and therapy. J. Pathol. 1999;197:127–137
  46. Yoneda K, Yamamoto T, Osaki T. p53- and p21-independent apoptosis of squamous cell carcinoma cells induced by 5-fluorouracil and radiation. Oral Oncol. 1998;34:529–537
  47. Tong D, Poot M, Hu D, Oda D. 5-Fluorouracil-induced apoptosis in cultured oral cancer cells. Oral Oncol. 2000;36:236–241
  48. Ohtani T, Hatori M, Ito H, Takizawa K, Kamijo R, Nagumo M. Involvement of caspases in 5-FU induced apoptosis in an oral cancer cell line. Anticancer Res. 2000;20:3117–3121
  49. Aota K, Azuma M, Yamashita T, Tamatani T, Motegi K, Ishimaru , et al.  5 Fluorouracil induces apoptosis through the suppression of NF-kappaB activity in human salivary gland cancer cells. Biochem. Biophys. Res. Commun. 2000;273:1168–1174
  50. Azuma M, Tamatani T, Ashida Y, Takashima R, Harada K, Sato M. Cisplatin induces apoptosis in oral squamous carcinoma cells by the mitochondria-mediated but not the NF-kappaB-suppressed pathway. Oral Oncol. 2003;39(3):282–289
  51. Mishima K, Nariai Y, Yoshimura Y. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression. Int. J. Cancer. 2003;105(5):593–600
  52. Chen XX, Lai MD, Zhang YL, Huang Q. Less cytotoxicity to combination therapy of 5 fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. World J. Gastroenterol. 2002;8(5):841–846
  53. Ita M, Okafuji M, Fukuda K, Mitsuoka K, Hanakita T, Hayatsu Y. Concurrent chemoradiotherapy with new platinum compound nedaplatin in oral cancer. Oral Oncol. 2003;39(2):144–149
  54. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971;93(9):2325–2327
  55. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets. 2003;3(3):193–203
  56. Mao Y, Desai SD, Ting CY, Hwang J, Liu LF. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem. 2001;276(44):40652–40658
  57. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001;61(15):5926–5932
  58. Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int. J. Cancer. 2003;106(1):108–115
  59. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostain. J. Antibiotics. 1976;29(1):1–6
  60. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Nat. Acad. Sci. (Wash.). 1999;96:4592–4597
  61. Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, et al.  Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int. J. Cancer. 2000;88(6):992–997
  62. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchiya H, et al.  A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J. Antibiotics. 1977;30:275–282
  63. Abiko Y, Arai J, Mitamura J, Kaku T. Alteration of proto-oncogenes during apoptosis in the oral squamous cell carcinoma cell line, SAS, induced by staurosporine. Cancer Lett. 1997;118:101–107
  64. McKeague AL, Wilson DJ, Nelson J. Staurosporine-induced apoptosis and hydrogen peroxide-induced necrosis in two human breast cell lines. Br. J. Cancer. 2003;88:125–131
  65. Dai G, Zhang Z, Zhou M, Yu S. The role of mitogen-activated protein kinase (MAPK) pathway in the action mechanism of PYM-induced KB cells apoptosis. Zhonghua Kou Qiang Yi Xue Za Zhi. 2002;37(2):97–98
  66. Yamamoto T, Yoneda K, Ueta E, Osaki T. The upregulation by peplomycin of signal transduction in human cells. Jpn. J. Pharmacol. 2001;87(1):41–50
  67. Okamura H, Morimoto H, Haneji T. Peplomycin-induced apoptosis in oral squamous carcinoma cells depends on bleomycin sensitivity. Oral Oncol. 2001;37(4):379–385
  68. McKenzie RC, Arthur JR, Beckett GJ. Selenium and the regulation of cell signaling, growth, and survival: molecular and mechanistic aspects. Antioxid. Redox. Signal. 2002;4(2):339–351
  69. Longtin R. Selenium for prevention: eating your way to better DNA repair?. J. Natl. Cancer Inst. 2003;95:98–100
  70. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, et al.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957–1963
  71. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Slate EH, Fischbach LA, et al.  Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev. 2002;11:630–639
  72. Waters DJ, Shen S, Cooley DM, Bostwick DG, Qian J, Combs GF, et al.  Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J. Natl. Cancer Inst. 2003;95:237–241
  73. Thirunavukkarasu C, Sakthisekaran D. Sodium selenite, dietary micronutrient, prevents the lymphocyte DNA damage induced by N-nitrosodiethylamine and phenobarbital promoted experimental hepatocarcinogenesis. J. Cell Biochem. 2003;88:578–588
  74. Ghose A, Fleming J, Harrison PR. Selenium and signal transduction: roads to cell death and anti-tumour activity. Biofactors. 2001;14:127–133
  75. Ghose A, Fleming J, El-Bayoumy K, Harrison PR. Enhanced sensitivity of human oral carcinomas to induction of apoptosis by selenium compounds: involvement of mitogen-activated protein kinase and Fas pathways. Cancer Res. 2001;61:7479–7487
  76. Fleming J, Ghose A, Harrison PR. Molecular mechanisms of cancer prevention by selenium compounds. Nutr. Cancer. 2001;40:42–49
  77. Dong Y, Ganther HE, Stewart C, Ip C. Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res. 2002;62:708–714
  78. Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc. Natl. Acad. Sci. USA. 2002;99:14548–14553
  79. Moustafa ME, Kumaraswamy E, Zhong N, Rao M, Carlson BA, Hatfield DL. Models for assessing the role of selenoproteins in health. J. Nat. 2003;133:2494S–2496S
  80. Reedijk J. Medicinal applications of heavy-metal compounds. Curr. Opin. Chem. Biol. 1999;3(2):236–240
  81. Reedijk J. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc. Natl. Acad. Sci. USA. 2003;100(7):3611–3616 Epub 2003 Mar 24.
  82. Demaurex N, Distelhorst C. Cell biology. Apoptosis––the calcium connection. Science. 2003;300(5616):65–67
  83. Whitfield JF, Bird RP, Chakravarthy BR, Isaacs RJ, Morley P. Calcium-cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. J. Cell Biochem. 1995;22(Suppl.):74–91
  84. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000;1(1):11–21
  85. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, et al.  BAX and BAK regulation of endoplasmic reticulum Ca++: a control point for apoptosis. Science. 2003;300(5616):135–139
  86. Arora A, Shukla Y. Induction of apoptosis by diallyl sulfide in DMBA-induced mouse skin tumors. Nutr. Cancer. 2002;44(1):89–94
  87. Bottone FG, Baek SJ, Nixon JB, Eling TE. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J. Nutr. 2002;132(4):773–778
  88. Kwon KB, Yoo SJ, Ryu DG, Yang JY, Rho HW, Kim JS, et al.  Induction of apoptosis by diallyl disulfide through activation of caspase-3 in human leukemia HL-60 cells. Biochem. Pharmacol. 2002;63(1):41–47
  89. Michalides RJ. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J. Clin. Pathol. 1999;52:555–568
  90. Williams HK. Molecular pathogenesis of oral squamous cell carcinoma. J. Clin. Path.: Mol. Pathol. 2000;53:165–172
  91. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ. Selective killing of cancer cells by beta-lapachone: direct checkpoint activation as a strategy against cancer. Proc. Natl. Acad. Sci. USA. 2003;100(5):2674–2678
  92. Katner AL, Gootam P, Hoang QB, Gnarra JR, Rayford W. A recombinant adenovirus expressing p27(Kip1) induces cell cycle arrest and apoptosis in human 786-0 renal carcinoma cells. J. Urol. 2002;168(2):766–773
  93. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol. Med. 2002;8(Suppl. 4):S68–S73
  94. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 2001;7(7):781–787
  95. Shillitoe EJ, Lapeyre JN, Adler-Storthz K. Gene therapy––its potential in the management of oral cancer. Eur. J. Cancer B Oral Oncol. 1994;30B(3):143–154
  96. Itoh M, Noutomi T, Chiba H, Mizuguchi J. BcI-xL antisene treatment sensitize Bcl-xL-overexpressing squamous cell carcinoma cells to carboplatin. Oral Oncol. 2002;38(8):752–756
  97. Folini M, Pennati M, Zaffaroni N. Targeting human telomerase by antisense oligonucleotides and ribozymes. Curr. Med. Chem. Anti-Canc. Agents. 2002;2(5):605–612
  98. Clayman GL, Liu TJ, Overholt SM, Mobley SR, Wang M, Janot F, et al.  Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch. Otolaryngol. Head Neck Surg. 1996;122(5):489–493
  99. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, et al.  Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 1998;16(6):2221–2232
  100. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene. Ther. 2001;12(8):861–870
  101. Merlin JL, Dolivet G, Dubessy C, Festor E, Parache RM, Verneuil L, et al.  Improvement of nonviral p53 gene transfer in human carcinoma cells using glucosylated polyethylenimine derivatives. Cancer Gene. Ther. 2001;8(3):203–210
  102. Hayashi K, Yokozaki H, Naka K, Yasui W, Lotan R, Tahara E. Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines. Jpn. J. Cancer Res. 2001;92(1):42–50
  103. Kaur J, Kaur J, Ralhan R. Induction of apoptosis by abrogation of HSP70 expression in human oral cancer cells. Int. J. Cancer. 2000;85(1):1–5
  104. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 2002;8(Suppl. 4):S19–S26
  105. O-Charoenrat P, Rhys-Evans PH, Modjtahedi H, Eccles SA. The role of c-erbB receptors in head and neck squamous cell carcinoma. Oral Oncol. 2002;38:627–640
  106. Bisacchi D, Beneilli R, Vanzetto C, Ferrari N, Tosetti F, Albini A. Anti-angiogenesis and angioprevention: mechanisms, problems and perspective. Cancer Detect. Prevent. 2003;27:229–238
  107. Faust RA, Tawfic S, Davis AT, Ahmed K. Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor. Oral Oncol. 1999;35(3):290–295
  108. Faust RA, Tawfic S, Davis AT, Bubash LA, Ahmed K. Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro. Head Neck. 2000;22(4):341–346
  109. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355–365
  110. Fujita M, Seta C, Fukuda J, Kobayashi S, Haneji T. Induction of apoptosis in human oral squamous carcinoma cell lines by protein phosphatase inhibitors. Oral Oncol. 1999;35(4):401–408
  111. Muraki Y, Tateishi A, Seta C, Fukuda J, Haneji T, Oya R, et al.  Fas antigen expression and outcome of oral squamous cell carcinoma. Int. J. Oral Maxillofac Surg. 2000;29(5):360–365
  112. Seta C, Fujita M, Muraki Y, Fukuda J, Kobayashi S, Haneji T. Fas expression and Fas monoclonal antibody-induced apoptosis in a human squamous cell carcinoma cell line, SCC-25. J. Oral Pathol. Med. 2000;29(6):271–278
  113. DeVita VT, Abou-alfa GK. Therapeutic implications of new biology. Cancer J. 2000;6(Suppl. 2):S113–S120
  114. Cancer treatment: new drugs, new hope. Harvard Health Lett. 2001;26:9
  115. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 2002;62(15):4300–4306
  116. Fogarty M. The reality of targeted therapies. Scientist. 2002;16:35–39
  117. de Bono JS, Rowinsky EK. Therapeutic targeting signal transduction for patients with colorectal carcinoma. Brit. Med. Bull. 2002;64:227–254
  118. Chung KT, Wong TY, Wei CI, Huang YW, Lin Y. Tannins and human health: a review. Crit. Rev. Food Sci. Nutr. 1998;38:421–464
  119. Milton K. Nutritional characteristics of wild primate foods: do the diets of our closest living relatives have lessons for us?. Nutrition. 1999;15(6):488–498
  120. World Cancer Research Fund/American Institute for Cancer Research . Food, Nutrition and the Prevention of Cancer: a Global Perspective. Washington, DC, USA: American Institute For Cancer Research; 1997;
  121. Manson MM. Cancer prevention––the potential for diet to modulate molecular signalling. Trends Mol. Med. 2003;9(1):11–18
  122. Pezzuto JM. Plant-derived anticancer agents. Biochem. Pharmacol. 1997;53(2):121–133
  123. Phytochemicals: Complementary and Alternatives Cancer Methods. American Cancer Society; 2000; [Chapter 7, pp. 163–304]
  124. Park EJ, Pezzuto JM. Botanicals in cancer chemoprevention. Cancer Metastasis Rev. 2002;21(3–4):231–255
  125. Marchand LL. Cancer preventive effects of flavonoids––a review. Biomed. Pharmacother. 2002;56:296–301
  126. Lampe JW. Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J. Nutr. 2003;133:956S–964S
  127. King A, Young G. Characteristics and occurrence of phenolic phytochemicals. Phytomedicine. 2000;7(6):483–491
  128. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev. 1998;56(11):317–333
  129. Nepka C, Asprodini E, Kouretas D. Tannins, xenobiotic metabolism and cancer chemoprevention in experimental animals. Eur. J. Drug Metab. Pharmacokinet. 1999;24:183–189
  130. Kuroda Y, Hara Y. Antimutagenic and anticarcinogenic activity of tea polyphenols. Mutat. Res. 1999;436:69–97
  131. Khafif A, Schantz SP, al-Rawi M, Edelstein D, Sacks PG. Green tea regulates cell cycle progression in oral leukoplakia. Head Neck. 1998;20:528–534
  132. Paschka AG, Butler R, Young CY. Induction of apoptosis in prostate cancer cell lines by the green teacomponent, (-)-epigallocatechin-3-gallate. Cancer Lett. 1998;130:1–7
  133. Chen ZP, Schell JB, Ho CT, Chen KY. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett. 1998;129:173–179
  134. Hsu S, Lewis JE, Borke JL, Singh B, Dickinson DP, Caughman GB, et al.  Chemopreventive effects of green tea polyphenols correlate with reversible induction of p57 expression. Anticancer Res. 2001;21:3743–3748
  135. Hsu S, Singh B, Lewis JE, Borke JL, Dickinson DP, Drake L, et al.  Chemoprevention of oral cancer by green tea. Gen. Dentistry. 2001;50(2):140–146
  136. Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 2001;7:4220–4229
  137. Fujiki H, Suganuma M, Okabe S, Sueoka E, Suga K, Imai K, et al.  A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-)-epigallocatechin gallate and green tea––a review. Cancer Detect Prev. 2000;24:91–99
  138. Sachinidis A, Seul C, Seewald S, Ahn H, Ko Y, Vetter H. Green tea compounds inhibit tyrosine phosphorylation of PDGF beta-receptor and transformation of A172 human glioblastoma. FEBS Lett. 2000;471:51–55
  139. Ahmad N, Cheng P, Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. 2000;275:328–334
  140. Kennedy DO, Kojima A, Yano Y, Hasuma T, Otani S, Matsui-Yuasa I. Growth inhibitory effect of green tea extract in Ehrlich ascites tumor cells involves cytochrome c release and caspase activation. Cancer Lett. 2001;166:9–15
  141. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. 2001;276:13322–13330
  142. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst. 1997;89:1881–1886
  143. Islam S, Islam N, Kermode T, Johnstone B, Mukhtar H, Moskowitz RW, et al.  Involvement of caspase-3 in epigallocatechin-3-gallate-mediated apoptosis of human chondrosarcoma cells. Biochem. Biophys. Res. Commun. 2000;270:793–797
  144. Hsu S, Bollag W, Lewis J, Huang Q, Singh B, Sharawy M, et al.  Tea polyphenols induce differentiation and proliferation in epidermal keratinocytes. J. Pharmacol. Exp. Ther. 2003;306:29–34
  145. Hsu S, Yu FS, Lewis J, Singh B, Borke J, Osaki T, et al.  Induction of p57 is required for cell survival when exposed to green tea polyphenols. Anticancer Res. 2002;22:4115–4120
  146. Keum YS, Kim J, Lee KH, Park KK, Surh YJ, Lee JM, et al.  Induction of apoptosis and caspase-3 activation by chemppreventive [6]-paradol and structurally related compounds in KB cells. Cancer Lett. 2002;177(1):41–47
  147. Chung WY, Jung YJ, Surh YJ, Lee SS, Park KK. Antioxidative and antitumor promoting effects of [6]-paradol and its homologs. Mutat. Res. 2001;496(1–2):199–206
  148. Katiyar SK, Agarwal R, Mukhtar H. Inhibition of tumor promoting in Sencar mouse skin by ethanol extract of Zingiber Officinale Rhizome. Cancer Res. 1996;56:1023–1033
  149. Rodriguez de Sotillo DV, Hadley M. Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J. Nutr. Biochem. 2002;13(12):717–726
  150. Jiang Y, Kusama K, Satoh K, Takayama E, Watanabe S, Sakagami H. Induction of cytotoxicity by chlorogenic acid in human oral tumor cell lines. Phytomedicine. 2000;7(6):483–491
  151. Das S. Garlic––a natural source of cancer preventive compounds. Asian Pac. J. Cancer Prev. 2002;3(4):305–311
  152. Thomson M, Ali M. Garlic [Allium sativum]: a review of its potential use as an anti-cancer agent. Curr. Cancer Drug Targets. 2003;3(1):67–81
  153. Balasenthil S, Rao KS, Nagini S. Garlic induces apoptosis during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Oral Oncol. 2002;38(5):431–436
  154. Hitosugi N, Hatsukari I, Ohno R, Hashimoto K, Mihara S, Mizukami S, et al.  Comparative analysis of apoptosis-inducing activity of codeine and codeinone. Anesthesiology. 2003;98(3):643–650
  155. Kawase M, Sakagami H, Furuya K, Kikuchi H, Nishikawa H, Motohashi N, et al.  Cell death-inducing activity of opiates in human oral tumor cell lines. Anticancer Res. 2002;22(1A):211–214
  156. Khachik F, Carvalho L, Bernstein PS, Muir GJ, Zhao D-Y, Katz NB. Chemistry, distribution and metabolism of tomato carotenoids and their impact on human health. Exp. Biol. Med. 2002;227:845–851
  157. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J. Natl. Cancer Inst. 1999;91(4):317–331
  158. Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp. Biol. Med. (Maywood). 2002;227(10):920–923
  159. Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp. Biol. Med. 2002;227:852–859
  160. Heber D. Colorful cancer prevention: a-carotene, lycopene, and lung cancer. Am. J. Clin. Nutr. 2000;72:901–902
  161. Vecchia CA. Tomatoes, lycopene intake and digestive tract and female hormone-related neoplasms. Exp. Biol. Med. 2002;227:860–863
  162. De Stefani E, Oreggia F, Boffetta P, Deneo-Pellegrini H, Ronco A, Mendilaharsu M. Tomatoes, tomato-rich foods, lycopene and cancer of the upper aerodigestive tract: a case-control in Uruguay. Oral Oncol. 2000;36:47–53
  163. Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, et al.  Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr. Cancer. 2000;36(1):101–111
  164. Livny O, Kaplan I, Reifen R, Polak-Charcon S, Madar Z, Schwartz B. Lycopene inhibits proliferation and enhances gap-junction communication of KB-1 human oral tumor cells. J. Nutr. 2002;132(12):3754–3759
  165. Muller K, Carpenter KL, Challis IR, Skepper JN, Arends MJ. Carotenoids induce apoptosis in the T-lymphoblast cell line Jurkat E6.1. Free Radic. Res. 2002;36(7):791–802
  166. Klaassen I, Braakhuis BJM. Anticancer activity and mechanisms of retinoids in oral and pharyngal cancer. Oral Oncol. 2002;38:532–542
  167. Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of the retinoids. In:  Sporn MB,  Roberts AB,  Goodman DS editor. The retinoids biology, chemistry and medicine. 2nd ed.. New York: Raven Press; 1994;p. 443–520
  168. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al.  13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med. 1986;315:1501–1505
  169. Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK. Molecular epidemiology of retinoid chemoprevention of head and neck cancer. J. Natl. Can. Inst. 1997;89:199–211
  170. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 1990;323(12):795–801
  171. Issing WJ, Struck R, Naumann A. Long-term follow-up of larynx leukoplakia under treatment with retinyl palmitate. Head Neck. 1996;18:560–565
  172. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett. 1988;40:93–101
  173. Mangelsdorf DJ. Vitamin A receptors. Nutr. Rev. 1994;52:S32–S44
  174. Mangelsdorf DJ, Umesono K, Evans RM. The retinoid receptors. In:  Sporn MB,  Roberts AB,  Goodman DS editor. The retinoids. biology, chemistry and medicine. 2nd ed.. New York: Raven Press; 1994;p. 319–349
  175. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10:940–954
  176. Xu C, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant and malignant head and neck tissues. Cancer Res. 1994;54:3580–3587
  177. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, et al.  Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by Isotretinoin. N. Engl. J. Med. 1995;332:1405–1410
  178. Oridate N, Esumi N, Lotan D, Hing WK, Rochett-Egly C, Chambon P, et al.  Implication of retinoic acid receptor gamma in squamous differentiation and response to retinoic acid in head and neck SqCC/Y1 squamous carcinoma cells. Oncogene. 1996;12:2019–2028
  179. Klaassen I, Brakenhoff Rh, Smeets SJ, Snow GB, Braakhuis BJ. Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines. Int. J. Cancer. 2001;92:661–665
  180. Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, et al.  Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin. Cancer Res. 2000;6:1563–1573
  181. Ulukaya E, Wood EJ. Fenretinide and its relation to cancer. Cancer Treat Rev. 1999;25:229–235
  182. Conley B, O’Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, et al.  Pilot trial of the safety, tolerability and retinoid levels of N-(4-hydroxyphenyl) retinamide in combinations with tamoxifen in patients at high risk for developing invasive breast cancer. J. Clin. Oncol. 2000;18:275–283
  183. Simoni D, Tolomeo M. Retinoids, apoptosis and cancer. Curr. Pharm. Des. 2001;7(17):1823–1837

PII: S1368-8375(03)00220-3

doi: 10.1016/j.oraloncology.2003.09.012

Oral Oncology
Volume 40, Issue 5 , Pages 461-473 , May 2004

Article Tools